Western Europe Opioids Market Analysed by CBR Pharma Insights in Topical Report Available at MarketPublishers.com
14 Nov 2014 • by Natalie Aster
LONDON – As of 2013, opioid revenues were estimated to be the highest in the United Kingdom, which accounted for 52% of the region’s total revenues, followed by Germany with a share of 20%. Spain held the lowest share in terms of both revenues (2.2%) and consumption (3.3%).
Although opioids are recognised as powerful pain killers, the potential for their misuse is high. As a consequence, all regulatory bodies strive for keeping a fine balance between enforcing rigid regulations that will crack down upon illicit opioid use but at the same time ensuring accessibility for genuine medicinal purposes. Amid concerns pertaining to inadequate pain management owing to low accessibility, there are also concerns over little clinical evidence of their role in chronic pain management. Still, novel abuse deterrent technologies offer an incentive to prescribe more opioids for pain management by mitigating concerns regarding misuse potential. The novel drugs and formulations’ approval has proved a new incentive to growth in opioid usage in the top 5 countries in Western Europe.
Topical research study “Opioids Market Overview to 2023 - Opioids in Western Europe” worked out by CBR Pharma Insights draws up an elaborate picture of the opioids market across the 5 major Western European countries – the UK, Germany, France, Spain, and Italy.
The report gives an in-depth overview of opioids’ role in pain management and substitution treatment, and sheds light on the specific usage constraints for both. A brief look at the latest approvals of major abuse deterrent drugs and their influence on consumption and market growth is provided. The comprehensive country snapshots contained in the study cover key regulations, market revenues, consumption, market forecasts and major barriers and drivers. Furthermore, the report is enriched with an insightful overview of advanced abuse deterrent technologies and exhaustive profiles of leading pipeline products.
Opioids Market Overview to 2023 - Opioids in Western Europe
Published: October, 2014
Price: US$ 2,995.00
Other Life Sciences Market Reports by CBR Pharma Insights:
- Biosimilars - Biosimilars on the Cusp of a New Era
- Adaptive Licensing - A Holistic Approach to Drug Development and Regulation
More topical studies by the publisher can be found at CBR Pharma Insights page.